[go: up one dir, main page]

SK283399B6 - Pyrazolový derivát, spôsob jeho prípravy, medziprodukt a farmaceutické prostriedky na jeho báze - Google Patents

Pyrazolový derivát, spôsob jeho prípravy, medziprodukt a farmaceutické prostriedky na jeho báze Download PDF

Info

Publication number
SK283399B6
SK283399B6 SK654-93A SK65493A SK283399B6 SK 283399 B6 SK283399 B6 SK 283399B6 SK 65493 A SK65493 A SK 65493A SK 283399 B6 SK283399 B6 SK 283399B6
Authority
SK
Slovakia
Prior art keywords
formula
alkyl
hydrogen
group
methyl
Prior art date
Application number
SK654-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK65493A3 (en
Inventor
Francis Barth
Pierre Casellas
Christian Congy
Serge Martinez
Murielle Rinaldi
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9431062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283399(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of SK65493A3 publication Critical patent/SK65493A3/sk
Publication of SK283399B6 publication Critical patent/SK283399B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK654-93A 1992-06-23 1993-06-23 Pyrazolový derivát, spôsob jeho prípravy, medziprodukt a farmaceutické prostriedky na jeho báze SK283399B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9207645A FR2692575B1 (fr) 1992-06-23 1992-06-23 Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.

Publications (2)

Publication Number Publication Date
SK65493A3 SK65493A3 (en) 1994-02-02
SK283399B6 true SK283399B6 (sk) 2003-07-01

Family

ID=9431062

Family Applications (1)

Application Number Title Priority Date Filing Date
SK654-93A SK283399B6 (sk) 1992-06-23 1993-06-23 Pyrazolový derivát, spôsob jeho prípravy, medziprodukt a farmaceutické prostriedky na jeho báze

Country Status (26)

Country Link
US (1) US5624941A (xx)
EP (1) EP0576357B1 (xx)
JP (1) JP3238801B2 (xx)
KR (1) KR100307050B1 (xx)
AT (1) ATE149489T1 (xx)
AU (1) AU664281B2 (xx)
BR (2) BR9302435A (xx)
CA (1) CA2098944C (xx)
CZ (1) CZ289487B6 (xx)
DE (1) DE69308395T2 (xx)
DK (1) DK0576357T3 (xx)
ES (1) ES2101258T3 (xx)
FI (1) FI113169B (xx)
FR (1) FR2692575B1 (xx)
GR (1) GR3023535T3 (xx)
HU (2) HU222577B1 (xx)
IL (2) IL106099A (xx)
MX (1) MX9303664A (xx)
MY (1) MY113022A (xx)
NO (1) NO302819B1 (xx)
NZ (1) NZ247961A (xx)
RU (1) RU2119917C1 (xx)
SK (1) SK283399B6 (xx)
TW (1) TW494096B (xx)
UA (1) UA27728C2 (xx)
ZA (1) ZA934511B (xx)

Families Citing this family (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713224B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CA2200981A1 (en) * 1994-10-04 1996-04-11 Hisashi Takasugi Urea derivatives and their use as acat-inhibitors
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
US5948777A (en) * 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
DE69910373T2 (de) * 1998-05-04 2004-04-01 The University Of Connecticut, Farmington Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
CN1561990A (zh) 1999-03-22 2005-01-12 免疫力药品有限公司 治疗免疫疾病
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
HU228678B1 (en) * 1999-08-03 2013-05-28 Ortho Mcneil Pharm Inc Process for preparing 1,5-diaryl-3-substituted pyrazoles
FR2799124B1 (fr) * 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CO5251397A1 (es) * 1999-10-08 2003-02-28 Smithkline Beecham Corp Inhibidores de fab i
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
AU773218B2 (en) * 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
CA2286442A1 (en) * 1999-10-15 2001-04-15 Universite De Montreal Compositions for increasing the concentration of cannabinoids as vasodilators and cardioprotectors againts ischaemia
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
MXPA02005103A (es) 1999-10-18 2003-09-25 Alexipharma Inc Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
EP1224173B1 (en) * 1999-10-18 2005-10-12 The University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7741365B2 (en) 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PT1268435E (pt) * 2000-03-23 2007-02-28 Solvay Pharm Bv Derivados de 4,5-diidro-1h-pirazol tendo actividade cb1-antagonista
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
EP1361876A4 (en) 2001-01-26 2004-03-31 Univ Connecticut NEW CANNABIMIMETIC LIGANDS
WO2002060447A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
MXPA03003534A (es) * 2001-03-22 2005-01-25 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1.
AU2002367773A1 (en) * 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
JP4312594B2 (ja) 2001-07-13 2009-08-12 ユニバーシティ オブ コネチカット 新規な二環式及び三環式カンナビノイド
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
KR100914113B1 (ko) * 2001-08-06 2009-08-27 아스트라제네카 아베 수불용성이고 활성인 안정한 나노입자 및 중쇄트리글리세리드(ｍｃｔ)와 같은 부형제를 포함하는수분산액
CA2458375A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
CA2457922A1 (en) * 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
MXPA03009439A (es) * 2001-09-21 2004-02-12 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
WO2003026647A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
AR036608A1 (es) * 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
BR0214031A (pt) * 2001-11-08 2004-10-19 Upjohn Co Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
US20040248956A1 (en) * 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
JP3813152B2 (ja) * 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
EP1490043A4 (en) * 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
JP2005531520A (ja) * 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
JP4459629B2 (ja) * 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
AU2003250106B2 (en) 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
CA2493313C (en) 2002-07-29 2010-03-09 F. Hoffmann-La Roche Ag Novel benzodioxoles
EP1542999A1 (en) 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US7319110B2 (en) * 2002-09-19 2008-01-15 Solvay Pharmaceuticals B.V. 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
SI1575951T1 (sl) * 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1583762B1 (en) 2003-01-02 2008-07-09 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
RU2339618C2 (ru) 2003-01-02 2008-11-27 Ф.Хоффманн-Ля Рош Аг Новые обратные агонисты рецептора св1
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
JPWO2004069824A1 (ja) * 2003-02-07 2006-05-25 第一製薬株式会社 ピラゾール誘導体
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
JP4041153B2 (ja) * 2003-05-07 2008-01-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドとその使用
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
EP1641779A1 (en) * 2003-06-18 2006-04-05 AstraZeneca AB 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
CN100368407C (zh) 2003-06-20 2008-02-13 霍夫曼-拉罗奇有限公司 作为cb1受体反激动剂的2-酰氨基苯并噻唑
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
ATE384058T1 (de) 2003-12-08 2008-02-15 Hoffmann La Roche Thiazolderivate
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
JP2007084437A (ja) * 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd アミノアルキルピラゾール誘導体
FR2864958B1 (fr) * 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
ES2349195T3 (es) 2004-01-28 2010-12-28 F. Hoffmann-La Roche Ag Espiro-benzodioxoles y su uso como antagonistas de cb1.
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
JP4208925B2 (ja) * 2004-02-20 2009-01-14 アストラゼネカ アクチボラグ 治療薬
EP1718613B1 (en) * 2004-02-24 2008-09-03 Glaxo Group Limited Pyridine derivatives and their use as cb2 receptor modulators
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
FR2867685B1 (fr) * 2004-03-17 2008-05-23 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive
EP1732904B1 (en) 2004-03-29 2014-03-19 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
RU2377238C2 (ru) * 2004-04-03 2009-12-27 Астразенека Аб Производные имидазола, активные в отношении рецептора св1
CA2564986A1 (en) 2004-05-10 2005-11-17 F. Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
FR2869905B1 (fr) 2004-05-10 2008-09-05 Sanofi Synthelabo Procede de preparation d'ester de l'acide 1,5-diphenylpyrazole carboxylique.
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
TW200602314A (en) * 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
EP1753764B1 (en) * 2004-06-09 2008-10-29 Glaxo Group Limited Pyrrolopyridine derivatives
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EA011307B1 (ru) 2004-07-12 2009-02-27 Кадила Хелзкэр Лимитед Трициклические производные пиразола в качестве модуляторов каннабиноидного рецептора
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006013962A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 抗血小板薬およびその製造方法
AU2005271527B2 (en) 2004-08-06 2009-08-27 Merck Sharp & Dohme Corp. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CA2578261A1 (en) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
GB0417910D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
US7572783B2 (en) * 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
AU2005298986A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
BRPI0517653A (pt) 2004-11-09 2008-10-14 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
AR054998A1 (es) 2004-12-03 2007-08-01 Schering Corp Piperazinas sustituidas como antagonistas de cb1, composicion farmaceutica y uso del compuesto para la manufactura de medicamentos
AR054417A1 (es) * 2004-12-23 2007-06-27 Astrazeneca Ab Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas.
US20080146614A1 (en) * 2004-12-23 2008-06-19 Leifeng Cheng Therapeutic Agents
FR2880023B1 (fr) * 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
WO2006087732A1 (en) * 2005-01-06 2006-08-24 Cadila Healthcare Limited An amorphous and three crystalline forms of rimonabant hydrochloride
EP2368881A1 (en) * 2005-01-10 2011-09-28 University of Connecticut Heteropyrazole analogs acting on cannabinoid receptors
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
FR2880890B1 (fr) * 2005-01-19 2007-03-30 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
FR2882054B1 (fr) * 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2882263B1 (fr) * 2005-02-23 2007-04-06 Sanofi Aventis Sa Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
PL1868999T3 (pl) 2005-04-06 2009-12-31 Hoffmann La Roche Pochodne pirydyno-3-karboksyamidu jako odwrotni agoniści CB1
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
AU2006253312B2 (en) 2005-05-30 2011-08-18 Msd K.K. Novel piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1896445B1 (en) * 2005-06-22 2010-11-10 F. Hoffmann-La Roche AG ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
FR2887550A1 (fr) * 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
FR2887548B1 (fr) * 2005-06-27 2007-09-21 Sanofi Aventis Sa Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
CA2613235A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP1904068A1 (en) * 2005-07-11 2008-04-02 N.V. Organon Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
WO2007009693A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A Combination of a substituted pyrazoline compound and a drug used in food-related disorders
EP1757588A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph of N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and its use as a cannabinoid receptor modulator
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
ES2326461B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr. Esteve, S.A. Polimorfo de n-priperidinil-5-(4-clorofenil)-1-(2,4-dicloforenil)-4,5-dihidro-1h-pirazol-3-carboxamida y su uso como modulador de receptores de cannabinoides.
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1910300A2 (en) * 2005-07-15 2008-04-16 Laboratorios del Dr. Esteve S.A. Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007131538A1 (en) * 2005-07-15 2007-11-22 Laboratorios Del Dr. Esteve, S.A. Azepane- or azocane-substituted pyrazoline compounds, their preparation and use as medicaments
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
EP1752149A1 (en) 2005-07-29 2007-02-14 Laboratorios Del Dr. Esteve, S.A. CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
AR055601A1 (es) * 2005-08-09 2007-08-29 Glaxo Group Ltd Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
CA2618468A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Process for the preparation of a stable dispersion of sub-micron particles in an aqueous medium
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
GB0518819D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
BRPI0616263A2 (pt) * 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
CN101277932A (zh) * 2005-09-30 2008-10-01 万有制药株式会社 芳基取代含氮杂环化合物
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
FR2894579B1 (fr) * 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
FR2894578B1 (fr) 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
CN100999517B (zh) * 2006-01-11 2010-12-15 北京摩力克科技有限公司 吡唑甲酰胺衍生物,药物组合物和其制备方法
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
BRPI0708264A2 (pt) * 2006-02-23 2011-05-24 Pfizer Ltd piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
JP4851546B2 (ja) * 2006-03-10 2012-01-11 ジェンリン ディスカバリー 肥満治療に有用なカンナビノイド受容体アンタゴニスト／インバースアゴニスト
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
WO2007121466A2 (en) * 2006-04-18 2007-10-25 Dr. Reddy's Laboratories Ltd. Process for preparing rimonabant
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
US7803799B2 (en) * 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
ATE469129T1 (de) * 2006-07-11 2010-06-15 Sanofi Aventis N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
WO2008032330A2 (en) * 2006-09-11 2008-03-20 Hetero Drugs Limited Improved process for rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
TWI339205B (en) * 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
WO2008062480A2 (en) * 2006-11-24 2008-05-29 Ind-Swift Laboratories Limited An improved process for the preparation of rimonabant
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
BRPI0720732A2 (pt) * 2006-12-18 2014-04-08 7Tm Pharma As Moduladores de receptor cb1
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
PL2114933T3 (pl) 2007-01-04 2012-02-29 Prosidion Ltd Piperydyny jako agoniści GPCR
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
US20080182877A1 (en) * 2007-01-05 2008-07-31 Westheim Raymond J H Rimonabant forms and methods of making the same
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
EP3255045A1 (en) * 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US8431609B2 (en) * 2007-02-19 2013-04-30 Darmesh Mahendrabhai Shah Process for preparation of pyrazole derivatives
WO2008101860A1 (en) * 2007-02-20 2008-08-28 Sandoz Ag Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US7705024B2 (en) * 2007-04-12 2010-04-27 National Health Research Institutes Oxadiazole compounds
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CN101314591B (zh) * 2007-05-30 2010-09-29 上海阳帆医药科技有限公司 吡唑类高选择性大麻受体-1拮抗剂和/或反向激动剂
US8604245B2 (en) 2007-06-04 2013-12-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2010529993A (ja) * 2007-06-15 2010-09-02 アイアールエム・リミテッド・ライアビリティ・カンパニー ＩＴＰＫｂ阻害剤としての化合物および組成物
EP2170846A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
CA2694264A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
FR2919184A1 (fr) * 2007-07-26 2009-01-30 Sanofi Aventis Sa L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
EP2176208B1 (en) * 2007-07-30 2015-01-21 Zynerba Pharmaceuticals, Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2009063495A2 (en) * 2007-09-20 2009-05-22 Cadila Healthcare Limited Substituted indole and its derivatives as cannabinoid modulators
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
EP2219664A1 (en) * 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2009099670A2 (en) 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
AU2009278838B2 (en) * 2008-08-06 2013-07-25 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TWI434686B (zh) * 2008-11-03 2014-04-21 Nat Health Research Institutes 咪唑－４－酮及咪唑－４－硫酮化合物
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
KR101070176B1 (ko) * 2009-01-13 2011-10-05 (주)에스에이치제약 Ｃｂ１에 길항 활성을 갖는 1ｈ-파이라졸-3-아마이드계 화합물 또는 1ｈ-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
WO2011044370A1 (en) * 2009-10-07 2011-04-14 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
EP2521721B1 (en) * 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US8785634B2 (en) 2010-04-26 2014-07-22 Merck Sharp & Dohme Corp Spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
CN102206182B (zh) * 2011-04-11 2013-03-13 中国药科大学 盐酸利莫那班的合成方法
CN102250006B (zh) * 2011-05-12 2014-03-05 范如霖 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP2014527973A (ja) 2011-09-23 2014-10-23 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 非生物的な植物ストレスに対する作用剤としての４−置換１−フェニルピラゾール−３−カルボン酸誘導体の使用
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
AR089656A1 (es) 2011-11-30 2014-09-10 Bayer Ip Gmbh Derivados de n-bicicloalquil- y n-tricicloalquil-(tio)-carboxamida fungicidas
IN2014KN02915A (xx) 2012-06-19 2015-05-08 Debiopharm Int Sa
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN113243374B (zh) 2012-10-02 2022-04-26 拜耳农作物科学股份公司 作为杀虫剂的杂环化合物
WO2014069554A1 (ja) * 2012-10-31 2014-05-08 東レ株式会社 キヌクリジンアミド誘導体及びその医薬用途
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014174457A1 (en) 2013-04-23 2014-10-30 Council Of Scientific & Industrial Research Pyrazole carboxylic acid analogues as anti-mycobacterial drug candidates
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
US10377718B2 (en) * 2014-06-06 2019-08-13 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
CN107207483B (zh) 2014-08-29 2020-10-30 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
CN106279029A (zh) * 2015-05-21 2017-01-04 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
WO2017144717A1 (en) 2016-02-26 2017-08-31 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
PE20190806A1 (es) 2016-10-12 2019-06-10 Res Triangle Inst Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11111698B2 (en) 2016-12-05 2021-09-07 Endura Products, Llc Multipoint lock
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR101877002B1 (ko) * 2017-03-06 2018-07-12 서울대학교 산학협력단 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
AU2019249560B2 (en) * 2018-04-04 2023-10-05 Japan Tobacco Inc. Heteroaryl-substituted pyrazole compound and medicinal use thereof
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
TW202033516A (zh) 2018-11-20 2020-09-16 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
ES8203350A1 (es) * 1979-11-16 1982-04-01 Morishita Pharma Procedimiento para la fabricacion de derivados del pirazol
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5164381A (en) * 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
US4898880A (en) * 1989-03-22 1990-02-06 Sterling Drug Inc. N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
IL105939A0 (en) * 1992-06-11 1993-10-20 Rhone Poulenc Agriculture Herbicidal compounds and compositions
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
HU222577B1 (hu) 2003-08-28
IL120517A0 (en) 1997-07-13
BR1100409A (pt) 1999-10-13
TW494096B (en) 2002-07-11
MX9303664A (es) 1994-01-31
UA27728C2 (uk) 2000-10-16
DK0576357T3 (da) 1997-09-15
ATE149489T1 (de) 1997-03-15
JP3238801B2 (ja) 2001-12-17
EP0576357B1 (fr) 1997-03-05
GR3023535T3 (en) 1997-08-29
MY113022A (en) 2001-11-30
CZ117293A3 (en) 1994-03-16
NZ247961A (en) 1995-08-28
CA2098944C (en) 1999-09-07
FR2692575A1 (fr) 1993-12-24
SK65493A3 (en) 1994-02-02
HU218797B (hu) 2000-12-28
FR2692575B1 (fr) 1995-06-30
HU9301851D0 (en) 1993-09-28
ZA934511B (en) 1994-02-22
BR9302435A (pt) 1994-01-11
HUT64526A (en) 1994-01-28
NO932296D0 (no) 1993-06-22
FI113169B (fi) 2004-03-15
ES2101258T3 (es) 1997-07-01
DE69308395T2 (de) 1997-10-16
FI932891A0 (fi) 1993-06-22
CA2098944A1 (en) 1993-12-24
DE69308395D1 (de) 1997-04-10
IL106099A (en) 1998-07-15
FI932891L (fi) 1993-12-24
US5624941A (en) 1997-04-29
KR100307050B1 (ko) 2001-11-30
NO302819B1 (no) 1998-04-27
JPH0673014A (ja) 1994-03-15
CZ289487B6 (cs) 2002-02-13
AU664281B2 (en) 1995-11-09
EP0576357A1 (fr) 1993-12-29
NO932296L (no) 1993-12-27
IL106099A0 (en) 1993-10-20
RU2119917C1 (ru) 1998-10-10
AU4143893A (en) 1994-01-06
KR940000433A (ko) 1994-01-03

Similar Documents

Publication Publication Date Title
SK283399B6 (sk) Pyrazolový derivát, spôsob jeho prípravy, medziprodukt a farmaceutické prostriedky na jeho báze
US6906080B1 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
US5462960A (en) Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present
TWI242004B (en) 1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
KR100223074B1 (ko) 3-아미도피라졸 유도체 및 그 제조방법과 그것을 함유한 약학 조성물
US5189045A (en) Aminopiperidine indanyl and benzocyclobutene compounds
CZ20012697A3 (cs) Deriváty pyrazolkarboxylové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
SK283706B6 (sk) Derivát pyrazolu, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom
CA2373510A1 (en) Pyrazole carboxamides useful for the treatment of obesity and other disorders
IE83893B1 (en) Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present
CZ290496B6 (cs) N-Piperidino-5-(4-chlorfenyl)-1-(2,4-dichlorfenyl)-4-methylpyrazol-3-karboxamid, způsob jeho přípravy a farmaceutický přípravek tento karboxamid obsahující
HU225156B1 (en) Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
US5661169A (en) 1-benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and the pharmaceutical compositions containing them
US4612318A (en) CNS-depressant and analgesic tricyclo-[pyrazolo-[3,4-6]-pyridine] derivatives and pharmaceutical compositions thereof
AU639043B2 (en) Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them
DE3700407A1 (de) Indolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
CA2450271A1 (en) Novel phenylalkyl diamine and amide analogs
SK42299A3 (en) N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
JPH04234369A (ja) ６−アルキルピリダジン誘導体、調製方法およびそれらを含有する医薬組成物
SI9300628A (sl) N-substituirani derivati azabicikloheptana, njihova priprava in uporaba

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120623